Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
255 articles with Aurinia (Formerly Known as Isotechnika Pharma Inc.)
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Dr. Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company for one year
Aurinia Pharmaceuticals Inc. reported its financial results for the fourth quarter and year ended December 31, 2018.
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. announced a host of activities, including an initiative with The National Kidney Foundation, designed to raise awareness for kidney disease.
Aurinia Pharmaceuticals Inc. announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES
Aurinia Pharmaceuticals Inc., announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST
Aurinia Pharmaceuticals Inc. today announced that it has entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to US$30,000,000.
Aurinia Pharmaceuticals Inc. today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc. today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.
AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule
Conference Call and webcast to follow
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities focused on raising awareness of lupus nephritis (LN)
Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes.
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Aurinia Pharmaceuticals Inc. announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference.
Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2017.